IDEAYA Biosciences Inc
IDYA24.440USD
-0.280-1.13%
Handelsschluss 09/17, 16:00（ET）Kurse um 15 Minuten verzögert
2.14BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über IDEAYA Biosciences Inc Unternehmen
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Unternehmensinformationen
BörsenkürzelIDYA
Name des UnternehmensIDEAYA Biosciences Inc
IPO-datumMay 23, 2019
CEOMr. Yujiro S. Hata
Anzahl der mitarbeiter131
WertpapierartOrdinary Share
GeschäftsjahresendeMay 23
Addresse7000 Shoreline Ct, Suite 350
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16504436209
Websitehttps://www.ideayabio.com/
BörsenkürzelIDYA
IPO-datumMay 23, 2019
CEOMr. Yujiro S. Hata
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
7.00M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Aktionärsstatistik
Aktualisiert: Sun, Aug 31
Aktualisiert: Sun, Aug 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
7.61%
Capital Research Global Investors
7.48%
Janus Henderson Investors
7.08%
Point72 Asset Management, L.P.
5.74%
Andere
57.10%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
7.61%
Capital Research Global Investors
7.48%
Janus Henderson Investors
7.08%
Point72 Asset Management, L.P.
5.74%
Andere
57.10%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
48.89%
Investment Advisor/Hedge Fund
31.84%
Hedge Fund
20.79%
Venture Capital
6.27%
Research Firm
4.17%
Individual Investor
0.90%
Pension Fund
0.82%
Bank and Trust
0.35%
Private Equity
0.16%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
2023Q1
290
47.36M
97.90%
-6.95M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
13.13M
14.99%
+167.11K
+1.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
8.17%
+286.75K
+4.18%
Mar 31, 2025
Capital Research Global Investors
2.73M
3.12%
+169.03K
+6.59%
Mar 31, 2025
Janus Henderson Investors
6.40M
7.31%
+544.14K
+9.29%
Mar 31, 2025
Point72 Asset Management, L.P.
4.41M
5.04%
+4.27M
+3048.93%
Jun 06, 2025
The Vanguard Group, Inc.
5.08M
5.8%
+14.54K
+0.29%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
4.77M
5.44%
-295.60K
-5.84%
Mar 31, 2025
Deerfield Management Company, L.P.
3.27M
3.73%
+531.55K
+19.43%
Mar 31, 2025
State Street Global Advisors (US)
3.45M
3.93%
+125.33K
+3.77%
Mar 31, 2025
Logos Global Management LP
3.50M
4%
+500.00K
+16.67%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
Tema Oncology ETF
2.26%
ALPS Medical Breakthroughs ETF
1.33%
SPDR S&P Biotech ETF
0.69%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
iShares Biotechnology ETF
0.19%
Avantis US Small Cap Equity ETF
0.18%
iShares Russell 2000 Value ETF
0.16%
Global X Russell 2000 ETF
0.08%
iShares Russell 2000 ETF
0.07%
Schwab U.S. Small-Cap ETF
0.06%
Mehr Anzeigen
Tema Oncology ETF
Anteil2.26%
ALPS Medical Breakthroughs ETF
Anteil1.33%
SPDR S&P Biotech ETF
Anteil0.69%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.39%
iShares Biotechnology ETF
Anteil0.19%
Avantis US Small Cap Equity ETF
Anteil0.18%
iShares Russell 2000 Value ETF
Anteil0.16%
Global X Russell 2000 ETF
Anteil0.08%
iShares Russell 2000 ETF
Anteil0.07%
Schwab U.S. Small-Cap ETF
Anteil0.06%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
